FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-β autoinduction

International Journal of Biochemistry and Cell Biology

Volumn 92, Issue , 2017, Pages 63-78

  Smith, Edward R ^a,b   Holt, Stephen G ^a,b   Hewitson, Tim D ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

FGF23; Fibroblast activation; Fibrosis; Kidney disease; Klotho; NFAT; TGF 1; TRPC6

Indexed keywords

CALCIUM; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLYCOSIDASE; PROTEIN ALPHA KLOTHO; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNCLASSIFIED DRUG; BETA GLUCURONIDASE; FGFR4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; KLOTHO PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL ACTIVATION; CELL DAMAGE; CELL DIFFERENTIATION; CONTROLLED STUDY; FIBROBLAST; FIBROGENESIS; IN VITRO STUDY; KIDNEY; MALE; MITOCHONDRION; MOUSE; MYOFIBROBLAST; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; RNA SEQUENCE; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HEK293 CELL LINE; HUMAN; INTRACELLULAR SPACE; METABOLISM; PATHOLOGY; URETER OBSTRUCTION;

ANIMALS; CALCIUM; FIBROBLAST GROWTH FACTORS; FIBROBLASTS; GLUCURONIDASE; HEK293 CELLS; HUMANS; INTRACELLULAR SPACE; KIDNEY; MALE; MICE; NFATC TRANSCRIPTION FACTORS; REACTIVE OXYGEN SPECIES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; TRPC6 CATION CHANNEL; URETERAL OBSTRUCTION;

EID: 85029719844     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2017.09.009     Document Type: Article

References (90)

1. Andrukhova, O., Slavic, S., Odorfer, K.I., Erben, R.G., Experimental myocardial infarction upregulates circulating fibroblast growth factor-23. J. Bone Miner. Res. 30 (2015), 1831–1839.
2. Arking, D.E., Krebsova, A., Macek, M. Sr., Macek, M. Jr., Arking, A., Mian, I.S., et al. Association of human aging with a functional variant of klotho. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 856–861.
3. Barnes, J.L., Gorin, Y., Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int. 79 (2011), 944–956.
4. Bhawan, J., Majno, G., The myofibroblast: possible derivation from macrophages in xanthogranuloma. Am. J. Dermatopathol. 11 (1989), 255–258.
5. Bloch, L., Sineshchekova, O., Reichenbach, D., Reiss, K., Saftig, P., Kuro-o, M., et al. Klotho is a substrate for alpha-, beta- and gamma-secretase. FEBS Lett. 583 (2009), 3221–3224.
6. Brookes, P.S., Yoon, Y., Robotham, J.L., Anders, M.W., Sheu, S.S., Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am. J. Physiol. Cell Physiol. 287 (2004), C817–C833.
7. Cha, S.K., Ortega, B., Kurosu, H., Rosenblatt, K.P., Kuro, O.M., Huang, C.L., Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 9805–9810.
8. Cha, S.K., Hu, M.C., Kurosu, H., Kuro-o, M., Moe, O., Huang, C.L., Regulation of renal outer medullary potassium channel and renal K(+) excretion by Klotho. Mol. Pharmacol. 76 (2009), 38–46.
9. Dai, B., David, V., Martin, A., Huang, J., Li, H., Jiao, Y., et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One, 7, 2012, e44161.
10. Davis, J., Burr, A.R., Davis, G.F., Birnbaumer, L., Molkentin, J.D., A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo. Dev. Cell 23 (2012), 705–715.
11. Doi, S., Zou, Y., Togao, O., Pastor, J.V., John, G.B., Wang, L., et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J. Biol. Chem. 286 (2011), 8655–8665.
12. de Jong, M.A., Mirkovic, K., Mencke, R., Hoenderop, J.G., Bindels, R.J., Vervloet, M.G., et al. Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis. Nephrol. Dial. Transplant. 32 (2017), 73–80.
13. Faul, C., Amaral, A.P., Oskouei, B., Hu, M.C., Sloan, A., Isakova, T., et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 121 (2011), 4393–4408.
14. Fliser, D., Kollerits, B., Neyer, U., Ankerst, D.P., Lhotta, K., Lingenhel, A., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 18 (2007), 2600–2608.
15. Ford, M.L., Smith, E.R., Tomlinson, L.A., Chatterjee, P.K., Rajkumar, C., Holt, S.G., FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol. Dial. Transplant. 27 (2012), 727–733.
16. Gooch, J.L., Gorin, Y., Zhang, B.X., Abboud, H.E., Involvement of calcineurin in transforming growth factor-beta-mediated regulation of extracellular matrix accumulation. J. Biol. Chem. 279 (2004), 15561–15570.
17. Grabner, A., Amaral, A.P., Schramm, K., Singh, S., Sloan, A., Yanucil, C., et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 22 (2015), 1020–1032.
18. Grabner, A., Schramm, K., Silswal, N., Hendrix, M., Yanucil, C., Czaya, B., et al. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. Sci. Rep., 7, 2017, 1993.
19. Grimwood, L., Masterson, R., Propagation and culture of renal fibroblasts. Methods Mol. Biol. 466 (2009), 25–37.
20. Gutierrez, O.M., Januzzi, J.L., Isakova, T., Laliberte, K., Smith, K., Collerone, G., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119 (2009), 2545–2552.
21. Hagel, M., Miduturu, C., Sheets, M., Rubin, N., Weng, W., Stransky, N., et al. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov. 5 (2015), 424–437.
22. Hao, H., Li, X., Li, Q., Lin, H., Chen, Z., Xie, J., et al. FGF23 promotes myocardial fibrosis in mice through activation of beta-catenin. Oncotarget 7 (2016), 64649–64664.
23. Hewitson, T.D., Boon, W.C., Simpson, E.R., Smith, E.R., Samuel, C.S., Estrogens do not protect, but androgens exacerbate, collagen accumulation in the female mouse kidney after ureteric obstruction. Life Sci. 158 (2016), 130–136.
24. Hewitson, T.D., Holt, S.G., Tan, S.J., Wigg, B., Samuel, C.S., Smith, E.R., Epigenetic modifications to H3K9 in renal tubulointerstitial cells after unilateral ureteric obstruction and TGF-beta1 stimulation. Front. Pharmacol., 8, 2017, 307.
25. Hofmann, T., Obukhov, A.G., Schaefer, M., Harteneck, C., Gudermann, T., Schultz, G., Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature 397 (1999), 259–263.
26. Hogan, P.G., Chen, L., Nardone, J., Rao, A., Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 17 (2003), 2205–2232.
27. Hu, M.C., Shi, M., Cho, H.J., Zhang, J., Pavlenco, A., Liu, S., et al. The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection. Kidney Int. 84 (2013), 468–481.
28. Hu, M.C., Shi, M., Gillings, N., Flores, B., Takahashi, M., Kuro, O.M., et al. Recombinant alpha-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. Kidney Int. 91 (2017), 1104–1114.
29. Imura, A., Iwano, A., Tohyama, O., Tsuji, Y., Nozaki, K., Hashimoto, N., et al. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett. 565 (2004), 143–147.
30. Isakova, T., Wahl, P., Vargas, G.S., Gutierrez, O.M., Scialla, J., Xie, H., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79 (2011), 1370–1378.
31. Isakova, T., Xie, H., Yang, W., Xie, D., Anderson, A.H., Scialla, J., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305 (2011), 2432–2439.
32. Kanellis, J., Ma, F.Y., Kandane-Rathnayake, R., Dowling, J.P., Polkinghorne, K.R., Bennett, B.L., et al. JNK signalling in human and experimental renal ischaemia/reperfusion injury. Nephrol. Dial. Transplant. 25 (2010), 2898–2908.
33. Kashiwagi, I., Morita, R., Schichita, T., Komai, K., Saeki, K., Matsumoto, M., et al. Smad2 and smad3 inversely regulate TGF-beta autoinduction in clostridium butyricum-activated dendritic cells. Immunity 43 (2015), 65–79.
34. Kendrick, J., Cheung, A.K., Kaufman, J.S., Greene, T., Roberts, W.L., Smits, G., et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J. Am. Soc. Nephrol. 22 (2011), 1913–1922.
35. Kim, S.J., Angel, P., Lafyatis, R., Hattori, K., Kim, K.Y., Sporn, M.B., et al. Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol. Cell. Biol. 10 (1990), 1492–1497.
36. Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390 (1997), 45–51.
37. Kuro-o, M., Klotho as a regulator of oxidative stress and senescence. Biol. Chem. 389 (2008), 233–241.
38. Liu, S., Tang, W., Zhou, J., Stubbs, J.R., Luo, Q., Pi, M., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 17 (2006), 1305–1315.
39. Liu, S., Vierthaler, L., Tang, W., Zhou, J., Quarles, L.D., FGFR3 and FGFR4 do not mediate renal effects of FGF23. J. Am. Soc. Nephrol. 19 (2008), 2342–2350.
40. Ma, F.Y., Liu, J., Nikolic-Paterson, D.J., The role of stress-activated protein kinase signaling in renal pathophysiology. Braz. J. Med. Biol. Res. 42 (2009), 29–37.
41. Mace, M.L., Gravesen, E., Nordholm, A., Hofman-Bang, J., Secher, T., Olgaard, K., et al. Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia. Kidney Int. 92 (2017), 165–178.
42. Mack, M., Yanagita, M., Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int. 87 (2015), 297–307.
43. Martin, A., Liu, S., David, V., Li, H., Karydis, A., Feng, J.Q., et al. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J. 25 (2011), 2551–2562.
44. Martin, A., David, V., Quarles, L.D., Regulation and function of the FGF23/klotho endocrine pathways. Physiol. Rev. 92 (2012), 131–155.
45. Masuda, Y., Ohta, H., Morita, Y., Nakayama, Y., Miyake, A., Itoh, N., et al. Expression of Fgf23 in activated dendritic cells and macrophages in response to immunological stimuli in mice. Biol. Pharm. Bull. 38 (2015), 687–693.
46. Matsumura, Y., Aizawa, H., Shiraki-Iida, T., Nagai, R., Kuro-o, M., Nabeshima, Y., Identification of the human klotho gene and its two transcripts encoding membrane and secreted klotho protein. Biochem. Biophys. Res. Commun. 242 (1998), 626–630.
47. Meng, X.M., Nikolic-Paterson, D.J., Lan, H.Y., TGF-beta: the master regulator of fibrosis. Nat. Rev. Nephrol. 12 (2016), 325–338.
48. Meng, X.M., Wang, S., Huang, X.R., Yang, C., Xiao, J., Zhang, Y., et al. Inflammatory macrophages can transdifferentiate into myofibroblasts during renal fibrosis. Cell. Death. Dis., 7, 2016, e2495.
49. Minguillon, J., Morancho, B., Kim, S.J., Lopez-Botet, M., Aramburu, J., Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-beta1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-beta1. J. Leukoc. Biol. 77 (2005), 748–758.
50. Mirams, M., Robinson, B.G., Mason, R.S., Nelson, A.E., Bone as a source of FGF23: regulation by phosphate. Bone 35 (2004), 1192–1199.
51. Monticelli, S., Rao, A., NFAT1 and NFAT2 are positive regulators of IL-4 gene transcription. Eur. J. Immunol. 32 (2002), 2971–2978.
52. Mukhopadhyay, P., Rajesh, M., Hasko, G., Hawkins, B.J., Madesh, M., Pacher, P., Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. Nat. Protoc. 2 (2007), 2295–2301.
53. Nakano, N., Hosokawa, H., Kohyama, M., Hozumi, N., NF-AT-mediated expression of TGF-beta1 in tolerant T cells. J. Immunol. 178 (2007), 3067–3075.
54. Neyra, J.A., Hu, M.C., AlphaKlotho and chronic kidney disease. Vitam. Horm. 101 (2016), 257–310.
55. Neyra, J.A., Hu, M.C., Potential application of klotho in human chronic kidney disease. Bone 100 (2017), 41–49.
56. Nijenhuis, T., Sloan, A.J., Hoenderop, J.G., Flesche, J., van Goor, H., Kistler, A.D., et al. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am. J. Pathol. 179 (2011), 1719–1732.
57. Ornitz, D.M., Itoh, N., The fibroblast growth factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 4 (2015), 215–266.
58. Quarles, L.D., Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat. Rev. Endocrinol. 8 (2012), 276–286.
59. Rahaman, S.O., Grove, L.M., Paruchuri, S., Southern, B.D., Abraham, S., Niese, K.A., et al. TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice. J. Clin. Invest. 124 (2014), 5225–5238.
60. Rebholz, C.M., Grams, M.E., Coresh, J., Selvin, E., Inker, L.A., Levey, A.S., et al. Serum fibroblast growth factor-23 is associated with incident kidney disease. J. Am. Soc. Nephrol. 26 (2015), 192–200.
61. Saliba, Y., Karam, R., Smayra, V., Aftimos, G., Abramowitz, J., Birnbaumer, L., et al. Evidence of a role for fibroblast transient receptor potential canonical 3 Ca2+ channel in renal fibrosis. J. Am. Soc. Nephrol. 26 (2015), 1855–1876.
62. Satoh, M., Nagasu, H., Morita, Y., Yamaguchi, T.P., Kanwar, Y.S., Kashihara, N., Klotho protects against mouse renal fibrosis by inhibiting Wnt signaling. Am. J. Physiol. Renal Physiol. 303 (2012), F1641–51.
63. Seo, K., Rainer, P.P., ShalkeyHahn, V., Lee, D.I., Jo, S.H., Andersen, A., et al. Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 1551–1556.
64. Seth, M., Zhang, Z.S., Mao, L., Graham, V., Burch, J., Stiber, J., et al. TRPC1 channels are critical for hypertrophic signaling in the heart. Circ. Res. 105 (2009), 1023–1030.
65. Shalhoub, V., Shatzen, E.M., Ward, S.C., Davis, J., Stevens, J., Bi, V., et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J. Clin. Invest. 122 (2012), 2543–2553.
66. Shi, M., Flores, B., Gillings, N., Bian, A., Cho, H.J., Yan, S., et al. AlphaKlotho mitigates progression of AKI to CKD through activation of autophagy. J. Am. Soc. Nephrol. 27 (2016), 2331–2345.
67. Shin, S.Y., Yang, H.W., Kim, J.R., Heo, W.D., Cho, K.H., A hidden incoherent switch regulates RCAN1 in the calcineurin-NFAT signaling network. J. Cell Sci. 124 (2011), 82–90.
68. Smith, E.R., McMahon, L.P., Holt, S.G., Fibroblast growth factor 23. Ann. Clin. Biochem. 51 (2014), 203–227.
69. Smith, E.R., Tan, S.J., Holt, S.G., Hewitson, T.D., FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts. Sci. Rep., 7, 2017, 3345.
70. Smith, E.R., The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin. J. Am. Soc. Nephrol. 9 (2014), 1283–1303.
71. Spichtig, D., Zhang, H., Mohebbi, N., Pavik, I., Petzold, K., Stange, G., et al. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int. 85 (2014), 1340–1350.
72. Sugiura, H., Yoshida, T., Shiohira, S., Kohei, J., Mitobe, M., Kurosu, H., et al. Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. Am. J. Physiol. Renal Physiol. 302 (2012), F1252–64.
73. Tan, S.J., Smith, E.R., Hewitson, T.D., Holt, S.G., Toussaint, N.D., The importance of klotho in phosphate metabolism and kidney disease. Nephrology (Carlton) 19 (2014), 439–449.
74. Ubaidus, S., Li, M., Sultana, S., de Freitas, P.H., Oda, K., Maeda, T., et al. FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. J. Electron Microsc. (Tokyo) 58 (2009), 381–392.
75. Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444 (2006), 770–774.
76. Vainikka, S., Joukov, V., Wennstrom, S., Bergman, M., Pelicci, P.G., Alitalo, K., Signal transduction by fibroblast growth factor receptor-4 (FGFR-4). Comparison with FGFR-1. J. Biol. Chem. 269 (1994), 18320–18326.
77. Vines, A., McBean, G.J., Blanco-Fernandez, A., A flow-cytometric method for continuous measurement of intracellular Ca(2 +) concentration. Cytometry A 77 (2010), 1091–1097.
78. Wang, Y., Kuro-o, M., Sun, Z., Klotho gene delivery suppresses Nox2 expression and attenuates oxidative stress in rat aortic smooth muscle cells via the cAMP-PKA pathway. Aging Cell 11 (2012), 410–417.
79. Wang, S., Meng, X.M., Ng, Y.Y., Ma, F.Y., Zhou, S., Zhang, Y., et al. TGF-beta/Smad3 signalling regulates the transition of bone marrow-derived macrophages into myofibroblasts during tissue fibrosis. Oncotarget 7 (2016), 8809–8822.
80. Wang, Y.Y., Jiang, H., Pan, J., Huang, X.R., Wang, Y.C., Huang, H.F., et al. Macrophage-to-myofibroblast transition contributes to interstitial fibrosis in chronic renal allograft injury. J. Am. Soc. Nephrol. 28 (2017), 2053–2067.
81. Winbanks, C.E., Darby, I.A., Kelynack, K.J., Pouniotis, D., Becker, G.J., Hewitson, T.D., Explanting is an ex vivo model of renal epithelial-mesenchymal transition. J. Biomed. Biotechnol., 2011, 2011, 212819.
82. Winn, M.P., Conlon, P.J., Lynn, K.L., Farrington, M.K., Creazzo, T., Hawkins, A.F., et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308 (2005), 1801–1804.
83. Wohrle, S., Bonny, O., Beluch, N., Gaulis, S., Stamm, C., Scheibler, M., et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J. Bone Miner. Res. 26 (2011), 2486–2497.
84. Wu, Y.L., Xie, J., An, S.W., Oliver, N., Barrezueta, N.X., Lin, M.H., et al. Inhibition of TRPC6 channels ameliorates renal fibrosis and contributes to renal protection by soluble klotho. Kidney Int. 91 (2017), 830–841.
85. Xie, Z., Singh, M., Singh, K., ERK1/2 and JNKs, but not p38 kinase, are involved in reactive oxygen species-mediated induction of osteopontin gene expression by angiotensin II and interleukin-1beta in adult rat cardiac fibroblasts. J. Cell. Physiol. 198 (2004), 399–407.
86. Xie, J., Cha, S.K., An, S.W., Kuro, O.M., Birnbaumer, L., Huang, C.L., Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat. Commun., 3, 2012, 1238.
87. Yoshiko, Y., Wang, H., Minamizaki, T., Ijuin, C., Yamamoto, R., Suemune, S., et al. Mineralized tissue cells are a principal source of FGF23. Bone 40 (2007), 1565–1573.
88. Yue, J., Mulder, K.M., Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a smad-dependent pathway. J. Biol. Chem., 275, 2000, 35656.
89. Zanchi, C., Locatelli, M., Benigni, A., Corna, D., Tomasoni, S., Rottoli, D., et al. Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ace inhibitor. PLoS One, 8, 2013, e70775.
90. Zhang, X., Ibrahimi, O.A., Olsen, S.K., Umemori, H., Mohammadi, M., Ornitz, D.M., Receptor specificity of the fibroblast growth factor family: the complete mammalian FGF family. J. Biol. Chem. 281 (2006), 15694–15700.